The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus

Medical Mycology

Volumn 48, Issue 1, 2010, Pages 48-55

  Van De Sande, Wendy W J ^a   Tavakol, Mehri ^a   Van Vianen, Wim ^a   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal susceptibility; Aspergillus fumigatus; Hyphae; XTT

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE; 2,3-BIS(2-METHOXY-4-NITRO-5-SULFOPHENYL)-5-((PHENYLAMINO)CARBONYL)-2H-TETRAZOLIUM HYDROXIDE; ANTIFUNGAL AGENT; ECHINOCANDIN; PYRIMIDINE DERIVATIVE; TETRAZOLIUM; TRIAZOLE DERIVATIVE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FUNGAL MORPHOLOGY; FUNGUS CONIDIA; FUNGUS HYPHAE; IN VITRO STUDY; NONHUMAN; ASPERGILLOSIS; DRUG EFFECTS; FUNGUS SPORE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PROCEDURES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; HUMANS; HYPHAE; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PYRIMIDINES; SPORES, FUNGAL; TETRAZOLIUM SALTS; TRIAZOLES; VORICONAZOLE;

ASPERGILLUS FUMIGATUS;

EID: 74949097747     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780802713497     Document Type: Article

References (28)

1. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-409.
2. Hope WW, Kruhlak MJ, Lyman CA, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for antifungal therapy. J Infect Dis 2007; 195: 455-466.
3. Doffman SR, Agrawal SG, Brown JS. Invasive pulmonary aspergillosis. Expert Rev Anti Infect Ther 2005; 3: 613-627.
4. CLSI. Clinical and Laboratory Standards Institute. R eference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. CLSI, Wayne, PA. 2002.
5. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41: 403-409.
6. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002; 40: 2101-2107.
7. Guarro J, Llop C, Aguilar C, Pujol I. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother 1997; 41: 2760-2762.
8. Pujol I, Fernandez-Ballart J, Guarro J. Effect of inoculum form on in vitro antifungal susceptibilities of Aspergillus spp. J Antimicrob Chemother 2001; 47: 715-718.
9. Lass-Florl C, Nagl M, Gunsilius E, et al. In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae. Mycoses 2002; 45: 166-169.
10. Lass-Florl C, Speth C, Kofl er G, et al. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. Int J Antimicrob Agents 2003; 21: 229-233.
11. Mowat E, Butcher J, Lang S, Williams C, Ramage G. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol 2007; 56: 1205-1212.
12. Meletiadis J, Mouton JW, Meis JF, et al. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39: 3402-3408.
13. van de Sande WW, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, van Belkum A. Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob Agents Chemother 2005; 49: 1364-1368.
14. van de Sande WW, Fahal AH, Riley TV, Verbrugh H, van Belkum A. In vitro susceptibility of Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisinin. J Antimicrob Chemother 2007; 59: 553-555.
15. Ahmed AO, van de Sande WW, van Vianen W, et al. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2-H-tetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother 2004; 48: 2742-2746.
16. Perkhofer S, Jost D, Dierich MP, Lass-Florl C. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob Agents Chemother 2008; 52: 1873-1875.
17. Perkhofer S, Lugger H, Dierich MP, Lass-Florl C. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. Antimicrob Agents Chemother 2007; 51: 791-793.
18. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Update 2005; 8: 344-358
19. Lass-Florl C, Nagl M, Speth C, et al. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001; 45: 124-128.
20. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005; 49: 1232-1235.
21. Yekutiel A, Shalit I, Shadkchan Y, Osherov N. In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2004; 48: 3279-3283.
22. Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004; 42: 3475-3482.
23. Imhof A, Balajee SA, Marr KA. New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol 2003; 41: 5683-5688
24. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007; 59: 230-237
25. Pfaller MA, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol. 2000; 38: 3359-3361.
26. Guinea J, Pelaez T, Alcala L, Bouza E. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2007; 57: 273-276
27. Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003; 41: 1126-1129.
28. Martin-Mazuelos E, Peman J, Valverde A, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003; 52: 365-370.